Cardiol Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRDL research report →
Range $8 – $8
Price Chart
About the company
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study.
- CEO
- David G. Elsley
- IPO
- 2019
- Employees
- 18
- HQ
- Oakville, ON, CA
Get TickerSpark's AI analysis on CRDL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $151.01M
- P/E
- -5.46
- Fwd P/E
- 3.92
- PEG
- -0.15
- P/S
- 0.00
- P/B
- 8.99
- EV/EBITDA
- -5.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -180.13%
- ROIC
- -148.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-34,316,296
- Net Income
- $-33,818,874+7.8%
- EPS
- $-0.39+23.5%
- OCF Growth
- +4.8%
- FCF Growth
- +4.8%
- 52W High
- $2.34
- 52W Low
- $0.88
- 50D MA
- $1.74
- 200D MA
- $1.29
- Beta
- 0.52
- RSI (14)
- 24
- Avg Volume
- 1.32M
No earnings-call transcripts are available for CRDL yet.
- Free Float
- 83.7%
- Shares Outstanding
- 115.27M
- Float Shares
- 96.50M
of shares held by institutions
49 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mmcap International Inc. Spc | 15.60M | ▲ 246.24K |
| Tejara Capital Ltd | 5.11M | ▼ 16.30K |
| Ikarian Capital, LLC | 3.33M | ▲ 600.00K |
| Boothbay Fund Management, LLC | 975.72K | ▲ 180.84K |
| Citadel Advisors LLC | 796.53K | ▼ 23.38K |
| Renaissance Technologies LLC | 772.84K | ▲ 543.03K |
| Two Sigma Investments, LP | 746.94K | ▲ 212.73K |
| Brokers International Financial Services, LLC. | 388.49K | ▼ 76.53K |
| Morgan Stanley | 355.03K | ▲ 104.61K |
| Goldman Sachs Group Inc | 333.90K | ▲ 1.50K |
| Sheets Smith Investment Management | 142.10K | ▲ 142.10K |
| Pvg Asset Management Corp | 107.17K | 0 |
Held by 1 ETFs
Biggest fund positions in CRDL by dollar value.
Our CRDL coverage
Recent articles, reports, and earnings notes.
No research on CRDL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRDL report →Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
prnewswire.com · Sep 23
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
prnewswire.com · Sep 16
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
zacks.com · Sep 14
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
prnewswire.com · Sep 10
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 9
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
zacks.com · Aug 25
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
zacks.com · Aug 24
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
marketbeat.com · Aug 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.